Skip to main content
. 2022 Apr 14;36(6):1625–1634. doi: 10.1038/s41375-022-01559-4

Fig. 5. 4-1BB only Luc90-CAR-T demonstrates anti-myeloma activity.

Fig. 5

A NSG mice were engrafted with MM.1S-CG cells and treated 24 days later with the original CD28/BBz Luc90-CAR-T (n = 5), Luc90-BBz-CAR-T (n = 8), CD19-CAR-T (n = 4) or were left untreated (n = 3) and monitored for survival. One Luc90-CAR-T mouse was censored due to cage flood. B Tumor burden measured by BLI. C NSG mice were engrafted with MM.1S-CG cells and treated 28 days later with 2 × 106 or 0.5 × 106 Luc90-BBz-CAR-T (n = 5), 2 × 106 or 0.5 × 106 CD19-CAR-T (n = 2 and 4, respectively) or left untreated (n = 5). Kaplan–Meier Survival shown. D, E Normalized BLI images shown. F In vitro killing of OPM2-CG cells after 48 h by Luc90-CAR-T and BCMA-CAR-T. G Mice were engrafted with 1 × 106 OPM2-CG cells and treated 18 days later with 2 × 106 Luc90-BBz-CAR-T or BCMA-CAR-T (CD28/BBz). Kaplan–Meier survival shown. H, I Longitudinal BLI was used to measure tumor burden. J Tumor free mice originally engrafted with OPM2-CG cells were re-challenged with 0.5 × 106 MM.1S-CG cells. Five of seven Luc90-BBz-CAR-T were tumor free and seven of seven BCMA-CAR-T mice were included in the re-challenge experiment. Five tumor-naive NSG mice were used as controls. Tumor burden assessed by BLI is shown and normalized images shown in (K).